Javascript must be enabled for the correct page display
Faculty of Medical Sciences

Effects of riboflavin supplementation on the gut microbiome composition of Crohn’s disease patients

Klaassen, M.A.Y. (Marjolein) (2018) Effects of riboflavin supplementation on the gut microbiome composition of Crohn’s disease patients. thesis, Medicine.

Full text available on request.

Abstract

Inflammatory Bowel Diseases (IBD) are chronic inflammatory disorders of the gastro-intestinal tract, characterized by periods of active (exacerbation) and quiescent (remission) disease. Currently, the pathophysiological mechanisms that trigger an exacerbation and subsequently progress the gut into an inflammatory state remain unknown and therefore the only therapies that are currently available, modify the patient’s immune system, rendering susceptibility to various complications. Recently, changes in the gut microbiome have been associated to IBD exacerbations. Moreover, it was shown that vitamin B2 (or riboflavin) was, besides its effect of reducing blood pro-inflammatory cytokines, able to target these IBD microbiome changes in vitro. More specifically, vitamin B2 induced the growth of the beneficial bacterium Faecalibacterium prausnitzii. To analyze whether riboflavin could reduce inflammation and change the taxonomical (which bacteria) and pathway (what they do) gut microbiome composition, I compared the microbiomes of 64 IBD patients before and three weeks after the intake of riboflavin, using state of the art shotgun metagenomic sequencing technique. After three weeks of riboflavin intake, the overall taxonomical and functional microbiome composition did not change. However, on an individual taxonomies and pathways level, the abundance of the taxonomical order Actinomycetales increased and the abundance of the pathway encoding the biosynthesis of tetrapyrrole moleucles decreased in IBD patients, consequently to riboflavin intake. The abundance of F. prausnitzii did not change after the study period. Since riboflavin only caused minor changes in the gut microbiome that do not have antiinflammatory properties, riboflavin does not need to be implemented as therapy of IBD patients.

Item Type: Thesis (Thesis)
Supervisor name: First supervisor: and Weersma, Prof. dr. R.K. and Second supervisor: and Vich Vila, Mr. Arnau MSc and Department of Gastroenterology and Hepatology
Faculty: Medical Sciences
Date Deposited: 25 Jun 2020 10:39
Last Modified: 25 Jun 2020 10:39
URI: https://umcg.studenttheses.ub.rug.nl/id/eprint/46

Actions (login required)

View Item View Item